dynavax technologies corp
(DVAX:Consolidated Issue listed on NASDAQ Capital Market)
Peggy V. Phillips
Independent Director and Chairman of Executive Compensation & Human Resources Committee, Tekmira Pharmaceuticals Corporation
|Age||Total Calculated Compensation||This person is connected to 12 board members in 2 different organizations across 4 different industries.|
See Board Relationships
Ms. Peggy V. Phillips served as a Director of Treasury at CCA Global Partners, Inc. Ms. Phillips served as an Executive Vice President and Chief Operating Officer of Immunex Corporation from October 1999 to July 2002. She served as a Senior Vice President and Chief Operating Officer of Immunex Research and Development Corporation, Immunex Corp.'s former wholly owned research and development subsidiary from 1991 to January 1995. Prior to her Chief Operating Officer role, ...
2929 Seventh StreetPhone: 510-848-5100
Berkeley, California 94710
Board Members Memberships*
Former Chief Operating Officer, Executive Vice President and Director
Former Director and Member of Audit Committee
Director, Chairperson of Compensation Committee and Member of Audit Committee
Former Independent Director and Member of Audit Committee
Independent Director and Chairman of Executive Compensation & Human Resources Committee
University Of Idaho
University Of Idaho
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Ali Mortazavi||Chief Executive and Director|
Silence Therapeutics plc
|Peter French B.Sc, M.Sc, Ph.D., MBA||Chief Executive Officer, Managing Director and Director|
Benitec Biopharma Limited
|Hans G. C. P. Schikan||Chief Executive Officer and Member of Management Board|
Prosensa Holding N.V.
|Mark W. Schwartz Ph.D.||Chief Executive Officer and President|
Galena Biopharma, Inc.
|Kleanthis G. Xanthopoulos Ph.D.||Chief Executive Officer, President, Principal Financial & Accounting Officer and Director|
Regulus Therapeutics Inc.
|$600.0K||Compensation as of Fiscal Year 2013.|